Hos kræftpatienter var Noxafil mere effektivt end fluconazol og itraconazol, idet infektion opstod hos 2% af patienterne i Noxafil- gruppen og 8% i sammenligningsgruppen.
The medicine was more effective than fluconazole or itraconazole in cancer patients, with 2% of patients developing an infection in the Noxafil group, and 8% in the comparator group.